Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
Open Access
- 1 October 2024
- Vol. 9 (10) , 103929
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Prevalence of Mismatch-Repair Deficiency in Rectal AdenocarcinomasNew England Journal of Medicine, 2022
- Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort studyEuropean Journal of Cancer, 2022
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal CancerNew England Journal of Medicine, 2022
- Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant ChemotherapyClinical Cancer Research, 2020
- Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant TherapyJAMA Oncology, 2019
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2018
- Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch RepairClinical Colorectal Cancer, 2017
- Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative managementBMC Cancer, 2015
- Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III TrialJournal of Clinical Oncology, 2011
- Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation TherapyAnnals of Surgery, 2004